Fecal fungal microbiota (mycobiome) study as a potential tool for Precision Medicine in Inflammatory Bowel Disease

BALDERRAMO DC; ROMAGNOLI PA; GRANLUND A. VAN B. ; CATALÁN-SERRA I.

GUT AND LIVER

EDITORIAL OFFICE GUT & LIVER

Lugar: Seoul ; Año: 2023

1976-2283

There is growing evidence of the role of fungal microbiota in the pathogenesis of Inflammatory bowel disease (IBD). Fungi can exert direct pro-inflammatory effects directly or by modifying the bacterial composition via interkingdom interactions. Although several studies have demonstrated alterations in the fecal fungal microbiota composition in IBD patients, there is a wide variation in the mycobiome in different populations, with no definite pattern that can define the mycobiome in IBD having yet been identified. Recent work has suggested that characterizing the fecal fungal composition may influence therapeutic decisions and help to predict outcomes in a subset of IBD patients. In this study, we review the current literature on the emerging role of fecal mycobiome as a potential tool for precision medicine in IBD.